Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II niraparib salvage treatment study in metastatic/recurrent/persistent cervical cancer
2019-001226-10Phase 2Terminated
- Sponsor
- Policlinico Gemelli
- Start
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of niraparib in Cervical Cancer (CC), sponsored by Policlinico Gemelli. Primary endpoint: objective response rate. Started Oct 2020; status: terminated.
02
Drugs
niraparib
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on 2019-001226-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001226-10.